ACS-ASTRO Felix Feng, MD Clinician Scientist Development Award

ASTRO and the American Cancer Society (ACS) were saddened to hear of the passing of Felix Feng, MD, on December 10, 2024. He was an expert in translational genomics and pre-clinical therapeutics for prostate cancer and an author on over 200 journal articles. Dr. Feng received his undergraduate degree from Stanford University, his medical degree at Washington University School of Medicine in St. Louis and completed his residency training in Radiation Oncology at the University of Michigan. He served as Professor of Radiation Oncology, Urology, and Medicine; George and Judy Marcus Distinguished Professor and Vice Chair for Translational Research in the Department of Radiation Oncology at the University of California, San Francisco. He also served as the Director, Benioff Initiative for Prostate Cancer Research and Associate Director of Clinical Translational Research with the Helen Diller Family Comprehensive Cancer Center. Dr. Feng was also a 2024 recipient of the ASTRO Mentorship Award.

To read more about Dr. Feng, please see these pieces honoring his legacy:

• NRG Oncology. Legacy Tribute: In Honor of Felix Feng, MD. December 11, 2024.
• UCSF News - Research. Felix Feng, Giant in the Field of Prostate Cancer, Dies at 48. January 21, 2025.
• UCSF Helen Diller Family Comprehensive Cancer Center News. In Memoriam: Felix Feng, MD. 
• The ASCO Post. Felix Feng, MD, Leader in Genitourinary Cancer, Dies at Age 48. February 25, 2025.
• Chu, C., Quigley, D. Felix Feng (1975–2024). Nat Cancer 6, 737 (2025). https://doi.org/10.1038/s43018-025-00961-y.

ASTRO and ACS collaboratively worked to offer a Clinician Scientist Development Award designated in his honor. The first award was given in early 2025 to Grace Blitzer, MD, of the University of Wisconsin-Madison.

2025 ACS-ASTRO Felix Feng, MD, Clinician Scientist Development Grant Winner Investigator: Grace Blitzer, MD Institution: University of Wisconsin-Madison Project Title: Pilot trial investigating the role of circulating tumor DNA as a risk stratification tool to guide of adjuvant therapy in endometrial cancer

If you are an aspiring clinician scientist, please consider applying for this award.

If you would like to contribute to the fund that supports these awards, please donate here.